ArticleToxicology reports2025
Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion (IR) injury in the brain is a major cause of brain damage and neurotoxicity, particularly in patients with hypertension and diabetes, where oxidative stress and inflammation play critical roles. This study investigated the effects of telmisartan, ertugliflozin and omaveloxolone, on cerebral ischemia reperfusion IR-induced damage and neurotoxicity through modulation of the nuclear factor erythroid 2-related factor 2/ heme oxygenase-1 (Nrf2/HO-1) signaling pathway. Forty-two rats were divided into seven groups, including controls and treatment groups that received the drugs before ischemia induction via bilateral common carotid artery occlusion (BCCAO) followed by reperfusion. All three agents markedly enhanced Nrf2 immunoreactivity through immunohistochemical analysis and heme oxygenase-1 (HO-1) gene expression in brain tissues compared to controls. They also attenuated neurotoxic outcomes by reducing histopathological damage and lowering inflammatory mediators such as Nuclear Factor kappa-B (NF-κB), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Matrix Metalloproteinase-9 (MMP-9). A significant negative correlation was observed between Nrf2 activation and the severity of neurotoxicity inflammatory markers. In silico analysis revealed strong binding through highly negative docking scores of telmisartan and ertugliflozin to Nrf2 negative regulators Keap1 and GSK-3β, supported by stable molecular dynamics simulations, suggesting direct inhibition. In conclusion, omaveloxolone, telmisartan, and ertugliflozin alleviate ischemia-reperfusion induced neurotoxicity via potential Nrf2-mediated antioxidant and anti-inflammatory mechanisms, highlighting their potential preventive role in conditions predisposing to stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.